Alumis' TYK2 drug succeeds in key psoriasis studies, will seek FDA approval
Alumis' TYK2 drug succeeds in key psoriasis studies, will seek FDA approval
Body unavailable. Use the original source.
Alumis' TYK2 drug succeeds in key psoriasis studies, will seek FDA approval
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.